甲磺酸伊马替尼治疗慢性粒细胞白血病的效果观察

Effect of Imatinib mesylate in treatment of chronic myeloid leukemia

目的:观察甲磺酸伊马替尼治疗慢性粒细胞白血病的临床效果。方法:选取50例慢性粒细胞白血病患者为研究对象,根据入院顺序将其分为观察组和对照组各25例。对照组采用常规药物联合化疗,观察组采用甲磺酸伊马替尼联合常规药物和化疗。比较两组临床治疗效果、外周血白细胞计数、血红蛋白含量、不良反应发生率。结果:两组外周血白细胞计数、血红蛋白含量均明显改善,且观察组改善程度明显大于对照组,差异有统计学意义(P<0.05);观察组临床治疗总有效率为88.00%(22/25),明显高于对照组的60.00%(15/25),差异有统计学意义(P<0.05);观察组不良反应发生率是24.00%(6/25),明显低于对照组的52.00%(13/25),差异有统计学意义(P<0.05)。结论:甲磺酸伊马替尼有利于降低慢性粒细胞白血病患者的外周血白细胞计数,提高其血红蛋白含量,治疗效果优于常规药物联合化疗,且安全性高。

Objective: To explore clinical effects of Imatinib mesylate in treatment of chronic myeloid leukemia. Methods: 50 patients with chronic myeloid leukemia were selected as the research objects, and divided into observation group (n=25) and control group (n=25) according to the order of admission. The observation group was treated with Imatinib mesylate combined with conventional drugs and chemotherapy, while the control group was treated with conventional drugs combined with chemotherapy. The clinical efficacy, peripheral white blood cell count, hemoglobin content and incidence of adverse reactions were compared between the two groups. Results: The peripheral white blood cell count and hemoglobin content of the two groups were significantly improved, the improvement degree of the observation group was significantly higher than that of the control group, and the difference was statistically significant (P<0.05). The total effective rate of the clinical treatment in the observation group was 88.00%(22/25), which was obviously higher than 60.00%(15/25) of the control group, and the difference was statistically significant (P<0.05). The incidence of adverse reactions in the observation group was 24.00%(6/25), which was significantly lower than 52.00%(13/25)of the control group, and the difference was statistically significant (P<0.05). Conclusions: Imatinib mesylate in the treatment of the patients with chronic myeloid leukemia is beneficial to reduce the peripheral white blood cell count and improve the hemoglobin content. Moreover, it is superior to the conventional drugs combined with chemotherapy with high safety.